LightDark Log in Sign up

‹ Back to screener

BIOCON.NS Biocon Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2025-08-21 ₹357.75
2026-08-21 ₹412.90
Change over window +15.42%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 51.3%
Trailing 20-day average 50.8%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 2187557 1122493 51.31%
2026-08-27 1713404 794668 46.38%
2026-08-26 2245587 1365829 60.82%
2026-08-25 3087232 1524343 49.38%
2026-08-24 1761155 997043 56.61%
2026-08-21 2225359 1265620 56.87%
2026-08-20 1981150 1168451 58.98%
2026-08-19 1683297 795512 47.26%
2026-08-18 2691030 1185755 44.06%
2026-08-17 3190219 1516740 47.54%
2026-08-14 3992844 2325866 58.25%
2026-08-13 4627924 2515565 54.36%
2026-08-12 3793310 1866520 49.21%
2026-08-11 1959909 1022637 52.18%
2026-08-10 2289723 1165819 50.92%
2026-08-07 5265823 2498011 47.44%
2026-08-06 10929015 2834028 25.93%
2026-08-05 3296172 1789073 54.28%
2026-08-04 2478487 1183448 47.75%
2026-08-03 3389704 1926712 56.84%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers BIOCON.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
05 Apr 2024 NEHAL VORA Employees/Designated Employees Pledge Pledge Creation 61827 15864808 0.04% XBRL
04 Apr 2024 SIVANANDAM K - Pledge Pledge Creation 7328 1880365 0.00% XBRL
02 Apr 2024 KIRAN KUMAR GANDHIRAJAN Employees/Designated Employees Sell Market Sale 19998 5286351 0.01% XBRL
02 Apr 2024 Akhilesh Nand Employees/Designated Employees Sell Market Sale 11000 2866050 0.01% XBRL
19 Mar 2024 SHASHI KANT TIWARI Employees/Designated Employees Buy ESOP 6792 1709207 0.00% XBRL
05 Mar 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 275800 0.01% XBRL
05 Mar 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 2000 541900 0.01% XBRL
05 Mar 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 5000 1415000 0.01% XBRL
29 Feb 2024 SANTOSH GOVINDRAO KATTI - Buy ESOP 20500 5628275 0.00% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 278550 0.01% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 277500 0.01% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 1000 277350 0.01% XBRL
29 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 2000 558400 0.01% XBRL
27 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 5000 1362500 0.01% XBRL
27 Feb 2024 MANEESH H GHILDYAL Employees/Designated Employees Sell Market Sale 2000 540900 0.01% XBRL
26 Feb 2024 Gayatri Nayak Employees/Designated Employees Sell Market Sale 5000 1357500 0.00% XBRL
23 Feb 2024 INDRANIL SEN Employees/Designated Employees Buy ESOP 94071 26452765 0.01% XBRL
23 Feb 2024 INDRANIL SEN Employees/Designated Employees Sell ESOP 39000 10528405 0.00% XBRL
23 Feb 2024 Biocon India Limited Employees Welfare Trust Other Sell ESOP 39000 10528405 0.33% XBRL
22 Feb 2024 MUKESH KAMATH K Employees/Designated Employees Sell Market Sale 5000 1494000 0.01% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers BIOCON.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹415.55 INR (live) · fetched 2026-08-23 21:39 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
174.69
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹415.55 / (₹3,856,000,000 / 1,621,000,000 shares) = ₹415.55 / ₹2.38 EPS
FY2025-26 · Annual filing
ROE
1.13%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹3,856,000,000 / ₹340,318,000,000 = 1.13%
FY2025-26 · Annual filing
Debt/Equity
0.44
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹148,247,000,000 / ₹340,318,000,000 = 0.44
FY2025-26 · Annual filing
Current Ratio
1.22
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹171,798,000,000 / ₹140,692,000,000 = 1.22
FY2025-26 · Annual filing
ROCE
3.77%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹18,411,000,000 / (₹340,318,000,000 + ₹148,247,000,000) = 3.77%
FY2025-26 · Annual filing
Dividend Yield
0.13%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹908,000,000 / 1,621,000,000 shares) / ₹415.55 = ₹0.56 / ₹415.55
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 7.0y actual) 17.4%
Net Profit (3y) -11.5%
Revenue (5y, 7.0y actual) 17.4%
Net Profit (5y) -11.5%
Revenue (10y, 7.0y actual) 17.4%
Net Profit (10y) -11.5%

Operating Margin Trend

Eroding

FY2018-19 19.8%
FY2019-20 19.0%
FY2020-21 16.8%
FY2021-22 16.7%
FY2022-23 15.9%
FY2023-24 17.6%
FY2024-25 17.6%
FY2025-26 10.9%

ROCE Trajectory

FY2018-19 N/A
FY2019-20 N/A
FY2020-21 N/A
FY2021-22 N/A
FY2022-23 4.4%
FY2023-24 6.3%
FY2024-25 5.9%
FY2025-26 3.6%

Earnings Quality

No persistent gap detected

Net Profit CAGR -12.18% vs CFO CAGR 14.10% over 4.0y (2022-03-31 → 2026-03-31); most recent year: Net Profit -61.95% vs CFO -50.90%

Sector-Relative Percentile (Healthcare)

ROE 7th
ROCE 4th
Debt/Equity 17th
P/E 2th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹3,917.10 Cr. ₹3,432.90 Cr. ₹3,590.40 Cr. ₹3,821.40 Cr. ₹4,417.00 Cr. ₹3,941.90 Cr. ₹4,295.50 Cr. ₹4,173.00 Cr. ₹4,516.60 Cr. ₹4,336.00 Cr. RevenueFromOperations
Net Profit ₹135.50 Cr. incl. minority ₹222.90 Cr. ₹659.70 Cr. incl. minority ₹861.80 Cr. ₹-16.00 Cr. incl. minority ₹27.10 Cr. ₹25.10 Cr. incl. minority ₹81.10 Cr. ₹344.50 Cr. incl. minority ₹459.40 Cr. ₹31.40 Cr. incl. minority ₹89.20 Cr. ₹84.50 Cr. incl. minority ₹132.80 Cr. ₹143.80 Cr. incl. minority ₹-51.80 Cr. ₹125.90 Cr. incl. minority ₹198.60 Cr. ₹141.10 Cr. incl. minority ₹136.80 Cr. ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers BIOCON.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent3856000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital1621000000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets171798000000.0
CurrentLiabilities140692000000.0
EquityAttributableToOwnersOfParent340318000000.0
BorrowingsCurrent + BorrowingsNoncurrent148247000000.0

My notes